|
1 |
Please provide a short description of the state-of-the-art and/or current trends in the field? How does the result fit into it? |
| The extended-release formulation treatment is an essential element of certain diseases. Formulating biologically active proteins (e.g. enzymes, hormones, and cytokines) as drugs poses a number of specific problems related to the preservation of biological activity through the conservation of higher order protein structures.
|
|
|
2 |
What is the problem/need/knowledge gap that the research result is responding to? How was it addressed before? |
| The invention is a novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds, which provides a way of the formulation of sustained release products. The result of using it is a designed drug-delivery, and an extended life quality for patients. | |
|
3 |
What is the potential for further research? |
|
|
|
|
4 |
What is the proposed method of IPR-protection? (patent, license, trademark etc.) |
| The patent family is based on patent application publication number WO2008HU00028 20080307. The European national phase is currently in progress.
|
|
|
5 |
What are the steps that need to be taken in order to secure the IPR-protection? What is the cost of IPR-protection? |
|
|
|
|
6 |
What is you overall assessment of the scientific maturity of the research result? |
| The invention is a novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds, which provides a way of the formulation of sustained release products.
|
|
KEYWORDS QUANTITATIVE ASSESSMENT (0-5).
| Please put X as appropriate. | 1 | 2 | 3 | 4 | 5 |
| Scientific maturity | X | ||||
| Synergies | X | ||||
| State-of-the-art/innovation | X | ||||
| IPR-potential | X |
Tivadar Lippényi
